Author:
Vilches Silvia,Martínez-Avial María,Méndez Irene,Gómez González Cristina,Espinosa María Ángeles
Publisher
Springer Science and Business Media LLC
Reference59 articles.
1. •• Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2021;42(16):1554–68 (This paper is a position statement of the European working group on myocardial and pericardial diseases about cardiac amyloidosis. Main principles of epidemiology, diagnosis, and therapeutic management of patients with cardiac amyloidosis are described. It should be one of the first papers to read when studying Cardiac amyloidosis.).
2. •• Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis. J Am Coll Cardiol. 2023;81(11):1076–126 (As mentioned above about the ESC position statement, this paper written by American college of cardiology experts is another keystone to learn about cardiac amyloidosis.).
3. Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Fail. 2019;6(6):1128–39.
4. González-López E, Gallego-Delgado M, Guzzo-Merello G, De Haro-del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–94.
5. Lindmark K, Pilebro B, Sundström T, Lindqvist P. Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic. ESC Heart Fail. 2021;8(1):745–9.